ImmuneResearch Market

Vilon

A synthetic dipeptide (Lys-Glu) from the Khavinson bioregulator family, studied for thymic and immune system bioregulation and geroprotective effects.

ImmuneThymusBioregulatorKhavinson

Also referenced as: KE, Lys-Glu

Also appears in: Longevity

Price compare
20 tracked offers across 20 vendors · 6 dosages
Best trust-adjusted value: Peptide Plugs · Strong trust · $1.80/mg
From
$1.80/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Aug 10
Current low$1.89/mg
Market median$2.70/mg
Current coverage10 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Vilon crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence15 certificate records mentioning this compound or product name9 provider-linked · 12 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Immune / inflammation research

Primary research area: Immune. Also surfaces under Longevity for browsing and discovery.

Aliases
2

KE, Lys-Glu

Signal depth
Medium

FDA label signal · 771 trials · 4731 PubMed results

Preclinical
Research evidence

Current evidence for Vilon is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Vilon has no clinical trials that name it and 4731 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
Established
Journal of Agricultural and Food Chemistry · 110 citationsAn Exploration of the Calcium-Binding Mode of Egg White Peptide, Asp-His-Thr-Lys-Glu, and In Vitro Calcium Absorption Studies of Peptide–Calcium ComplexJournal ArticleCardiac morphology and flow dynamics in children born to hypertensive pregnancies.Journal ArticleAconitum tanguticum (Maxim.) Stapf.: a review of its traditional uses, chemical constituents, and pharmacological effects.Journal ArticleEvidence that myoglobin PO(2) is a non-invasive measure of in vivo skeletal muscle mitochondrial PO(2) during exercise in humans.Journal ArticleHo'oulu Me Ke Ikaika: A Community-Support Group that Improves Long-Term Emotional and Social Health of Adolescent and Young Adult Survivors of Childhood Cancer.Journal ArticlePolarity-dependent interactions and structural organization in konjac glucomannan blends with pectin, carboxymethyl cellulose and ethyl cellulose.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is Vilon?

Vilon is a synthetic dipeptide with the sequence Lys-Glu (KE), the shortest peptide in the Khavinson bioregulator family. It is classified as a thymus and immune system bioregulator. Despite being only two amino acids, the Khavinson group proposes it has tissue-specific biological activity.

How it works

  • Immune modulation — Vilon is theorized to support thymic function and T-lymphocyte maturation through tissue-specific gene regulation (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
  • Geroprotective effects — in the Khavinson framework, KE dipeptide is proposed to interact with DNA in thymocytes and modulate gene expression relevant to immune senescence (Khavinson, Gerontology, 2005)
  • Thymic involution — the thymus progressively atrophies with age; Vilon is theorized to counteract this process, though direct evidence is limited to cell culture and animal studies from the Khavinson group

Research status

  • Khavinson (2005) reviewed peptide bioregulators including the KE dipeptide (Gerontology, 51(2):70–75)
  • Khavinson et al. (2002) reported effects of short peptides on thymocyte chromatin in aging (Bulletin of Experimental Biology and Medicine, 133(5):473–475)
  • No independent Western replication studies or clinical trials

Key considerations

  • The smallest Khavinson bioregulator — only 2 amino acids, raising questions about specificity and mechanism
  • Part of the same bioregulator family as Thymalin (the full thymic extract) and Thymagen
  • Available from research vendors as lyophilized powder or capsules